There is still much progress to be made in understanding the underlying mechanisms of brain metastasis development and its optimal therapy in non–small cell lung cancer (NSCLC); it is very important to expand research in this area because brain metastasis strongly affects patients' quality of life and overall survival. This editorial reviews the available data in the context of a recent meta‐analysis of the pivotal IMpower130, IMpower131, and IMpower150 studies, which explores metastatic epidermal growth factor receptor and anaplastic lymphoma kinase wild‐type NSCLC to determine potential preventative factors and risk factors for the development of brain metastasis, specifically the question of whether immunotherapy (the anti–programmed death ligand 1 antibody, atezolizumab in particular) plays a role in preventing brain metastasis.

中文翻译：

---

转移性非小细胞肺癌的免疫治疗：真的是理所当然的吗？

在了解非小细胞肺癌（NSCLC）脑转移发展的潜在机制及其最佳治疗方面仍有很多进展；扩大该领域的研究非常重要，因为脑转移强烈影响患者的生活质量和总体生存率。这篇社论回顾了最近对关键 IMpower130、IMpower131 和 IMpower150 研究进行荟萃分析的现有数据，该研究探讨了转移性表皮生长因子受体和间变性淋巴瘤激酶野生型 NSCLC，以确定潜在的预防因素和危险因素脑转移的发展，特别是免疫疗法（抗程序性死亡配体 1 抗体，特别是 atezolizumab）是否在预防脑转移中发挥作用的问题。